Evicenter
MarkdownMedical informationP&T meetings
Juvmo (tavapadon)

Parkinson's disease

Also known as CVL-751
Manufacturer
AbbVie
Last updated
221 sources

Section 6 of 6

References

221 sources

  1. Aamodt et al. (2024) (opens in a new tab)
  2. AAN (2021) (opens in a new tab)
  3. Aarsland et al. (2010) (opens in a new tab)
  4. AbbVie approval press release (2026) (opens in a new tab)
  5. AbbVie Cerevel acquisition completion release (2024) (opens in a new tab)
  6. AbbVie comments to ICER (2026) (opens in a new tab)
  7. AbbVie earnings call transcript (2026) (opens in a new tab)
  8. AbbVie Form 10-K (2026) (opens in a new tab)
  9. AbbVie JUVMO prescriber access and support page (2026) (opens in a new tab)
  10. AbbVie JUVMO prescriber website (2026) (opens in a new tab)
  11. AbbVie press release (2025) (opens in a new tab)
  12. AbbVie TEMPO-1 topline release (2024) (opens in a new tab)
  13. AbbVie TEMPO-2 topline release (2024) (opens in a new tab)
  14. AbbVie third-quarter earnings call transcript (2026) (opens in a new tab)
  15. AbbVie Wholesale Acquisition Cost Price List (2026) (opens in a new tab)
  16. Ahlskog and Muenter (2001) (opens in a new tab)
  17. Albarmawi et al. (2022) (opens in a new tab)
  18. Allen et al. (2013) (opens in a new tab)
  19. American Academy of Neurology (2020) (opens in a new tab)
  20. Antonini et al. (2008) (opens in a new tab)
  21. Antonini et al. (2018) (opens in a new tab)
  22. Armstrong and Okun (2020) (opens in a new tab)
  23. Arnold et al. (2025) (opens in a new tab)
  24. ARY News (2026) (opens in a new tab)
  25. Azilect prescribing information (2020) (opens in a new tab)
  26. Bain Capital (2018) (opens in a new tab)
  27. Barone et al. (2009) (opens in a new tab)
  28. Benzinga (2026) (opens in a new tab)
  29. Berg et al. (2015) (opens in a new tab)
  30. Bezard et al. (2024) (opens in a new tab)
  31. Bjornestad et al. (2016) (opens in a new tab)
  32. Bjornestad et al. (2017) (opens in a new tab)
  33. Bloem et al. (2021) (opens in a new tab)
  34. Broen et al. (2016) (opens in a new tab)
  35. CADTH (2020) (opens in a new tab)
  36. California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2026) (opens in a new tab)
  37. Centers for Medicare and Medicaid Services Part D Spending by Drug for branded adjunctive therapies (2026) (opens in a new tab)
  38. Centers for Medicare and Medicaid Services Part D Spending by Drug for monoamine oxidase B inhibitors, catechol-O-methyltransferase inhibitors, and amantadine (2026) (opens in a new tab)
  39. Cerevel Therapeutics Form 10-K (2024) (opens in a new tab)
  40. Cerevel Therapeutics press release (2024) (opens in a new tab)
  41. Cerevel Therapeutics statistical analysis plan (2024) (opens in a new tab)
  42. Cerevel Therapeutics TEMPO-1 protocol (2023) (opens in a new tab)
  43. Cerevel Therapeutics TEMPO-1 statistical analysis plan (2024) (opens in a new tab)
  44. Cerevel Therapeutics TEMPO-2 protocol (2023) (opens in a new tab)
  45. Cerevel Therapeutics TEMPO-2 statistical analysis plan (2024) (opens in a new tab)
  46. Cerevel Therapeutics trial protocol (2023) (opens in a new tab)
  47. Chapuis et al. (2005) (opens in a new tab)
  48. Chaudhuri et al. (2015) (opens in a new tab)
  49. ClinicalTrials.gov NCT01981694 (opens in a new tab)
  50. ClinicalTrials.gov NCT02066909 (opens in a new tab)
  51. ClinicalTrials.gov NCT02224664 (opens in a new tab)
  52. ClinicalTrials.gov NCT02224664 results (opens in a new tab)
  53. ClinicalTrials.gov NCT02373072 (opens in a new tab)
  54. ClinicalTrials.gov NCT02687542 (opens in a new tab)
  55. ClinicalTrials.gov NCT02687542 results (opens in a new tab)
  56. ClinicalTrials.gov NCT02847650 (opens in a new tab)
  57. ClinicalTrials.gov NCT03121664 (opens in a new tab)
  58. ClinicalTrials.gov NCT03185481 (opens in a new tab)
  59. ClinicalTrials.gov NCT04201093 (opens in a new tab)
  60. ClinicalTrials.gov NCT04201093 results (opens in a new tab)
  61. ClinicalTrials.gov NCT04223193 (opens in a new tab)
  62. ClinicalTrials.gov NCT04223193 results (opens in a new tab)
  63. ClinicalTrials.gov NCT04241393 (opens in a new tab)
  64. ClinicalTrials.gov NCT04295642 (opens in a new tab)
  65. ClinicalTrials.gov NCT04542499 (opens in a new tab)
  66. ClinicalTrials.gov NCT04542499 results (opens in a new tab)
  67. ClinicalTrials.gov NCT04760769 (opens in a new tab)
  68. ClinicalTrials.gov NCT05404529 (opens in a new tab)
  69. ClinicalTrials.gov NCT05404542 (opens in a new tab)
  70. ClinicalTrials.gov NCT05581823 (opens in a new tab)
  71. ClinicalTrials.gov NCT05610189 (opens in a new tab)
  72. ClinicalTrials.gov NCT06895356 (opens in a new tab)
  73. ClinicalTrials.gov NCT07158827 (opens in a new tab)
  74. CMS Quality Payment Program measure 291 (2026) (opens in a new tab)
  75. CMS Quality Payment Program measure 293 (2026) (opens in a new tab)
  76. Corvol et al. (2018) (opens in a new tab)
  77. Covington et al. (2016) (opens in a new tab)
  78. Dahodwala et al. (2017) (opens in a new tab)
  79. Dahodwala et al. (2021) (opens in a new tab)
  80. de Bie et al. (2025) (opens in a new tab)
  81. Devraj et al. (2024) (opens in a new tab)
  82. Dickson (2012) (opens in a new tab)
  83. Dodel et al. (2003) (opens in a new tab)
  84. Entacapone tablets prescribing information (2023) (opens in a new tab)
  85. Etminan et al. (2001) (opens in a new tab)
  86. Fahn et al. (2004) (opens in a new tab)
  87. FDA Novel Drug Therapy Approvals (2026) (opens in a new tab)
  88. Fernandez et al. (2023) (opens in a new tab)
  89. Fernandez et al. (2025) (opens in a new tab)
  90. Fernandez et al. (2026a) (opens in a new tab)
  91. Fernandez et al. (2026b) (opens in a new tab)
  92. Fernandez et al. supplementary appendix (2026a) (opens in a new tab)
  93. Forsaa et al. (2010) (opens in a new tab)
  94. Forsaa et al. (2015) (opens in a new tab)
  95. Fox et al. (2018) (opens in a new tab)
  96. Fox et al. (2025) (opens in a new tab)
  97. Frazer et al. (2023) (opens in a new tab)
  98. Frequin et al. (2024) (opens in a new tab)
  99. Gage et al. (2003) (opens in a new tab)
  100. GBD 2016 Parkinson's Disease Collaborators (2018) (opens in a new tab)
  101. Gerfen (2022) (opens in a new tab)
  102. Gocovri prescribing information (2026) (opens in a new tab)
  103. Goetz et al. (2008) (opens in a new tab)
  104. Gonzalez et al. (2022) (opens in a new tab)
  105. Gray et al. (2019) (opens in a new tab)
  106. Gros et al. (2025) (opens in a new tab)
  107. Gusovsky et al. (2024) (opens in a new tab)
  108. Hansen et al. (2021) (opens in a new tab)
  109. Harrison-Jones et al. (2025) (opens in a new tab)
  110. Hauser et al. (2000) (opens in a new tab)
  111. Hauser et al. (2004) (opens in a new tab)
  112. Hauser et al. (2011) (opens in a new tab)
  113. Hauser et al. (2014) (opens in a new tab)
  114. Hauser et al. (2025) (opens in a new tab)
  115. Hechtner et al. (2014) (opens in a new tab)
  116. Heinzel et al. (2019) (opens in a new tab)
  117. Hellmers et al. (2025) (opens in a new tab)
  118. Hely et al. (2005) (opens in a new tab)
  119. Hely et al. (2008) (opens in a new tab)
  120. Hickey et al. (2017) (opens in a new tab)
  121. Hjalte et al. (2021) (opens in a new tab)
  122. Hjalte et al. (2025) (opens in a new tab)
  123. Höglinger et al. (2024) (opens in a new tab)
  124. Höglinger et al. (2025) (opens in a new tab)
  125. Horváth et al. (2015) (opens in a new tab)
  126. Horváth et al. (2017) (opens in a new tab)
  127. Houghton et al. (2019) (opens in a new tab)
  128. ICER evidence report (2026) (opens in a new tab)
  129. ICER public meeting slides (2026) (opens in a new tab)
  130. Jimenez-Shahed et al. (2025) (opens in a new tab)
  131. Johnsrud et al. (2021) (opens in a new tab)
  132. Juvmo prescribing information (2026) (opens in a new tab)
  133. Kalf et al. (2012) (opens in a new tab)
  134. Kalilani et al. (2019) (opens in a new tab)
  135. Kaye et al. (2025) (opens in a new tab)
  136. Kim et al. (2020) (opens in a new tab)
  137. Kordower et al. (2013) (opens in a new tab)
  138. Kowal et al. (2013) (opens in a new tab)
  139. Krishna et al. (2023) (opens in a new tab)
  140. Kwak et al. (2024) (opens in a new tab)
  141. Lange et al. (2026) (opens in a new tab)
  142. Leiter et al. (2026) (opens in a new tab)
  143. Lewis et al. (2023) (opens in a new tab)
  144. Łobińska and Sławek (2026) (opens in a new tab)
  145. Macleod et al. (2014) (opens in a new tab)
  146. Macleod et al. (2026) (opens in a new tab)
  147. Makkos et al. (2018) (opens in a new tab)
  148. Marras et al. (2018) (opens in a new tab)
  149. Martínez-Fernández et al. (2020) (opens in a new tab)
  150. Martinez-Martin et al. (2011) (opens in a new tab)
  151. Martinez-Martin et al. (2019) (opens in a new tab)
  152. Medicaid.gov National Average Drug Acquisition Cost for branded and generic comparators (2026) (opens in a new tab)
  153. Medicaid.gov National Average Drug Acquisition Cost for rotigotine, rasagiline, selegiline, entacapone, and amantadine (2026) (opens in a new tab)
  154. Mirapex prescribing information (2021) (opens in a new tab)
  155. Neupro prescribing information (2021) (opens in a new tab)
  156. NeurologyLive (2025) (opens in a new tab)
  157. Nguyen et al. (2025) (opens in a new tab)
  158. NICE (2017) (opens in a new tab)
  159. Nourianz prescribing information (2023) (opens in a new tab)
  160. Noyes et al. (2004) (opens in a new tab)
  161. Ondo et al. (2026) (opens in a new tab)
  162. Ongentys prescribing information (2025) (opens in a new tab)
  163. Pahwa and Isaacson (2020) (opens in a new tab)
  164. Pahwa et al. (2023) (opens in a new tab)
  165. Pahwa et al. (2025) (opens in a new tab)
  166. Pahwa et al. (2026) (opens in a new tab)
  167. Palma and Gomez Casanovas (2026) (opens in a new tab)
  168. Pastino et al. (2022) (opens in a new tab)
  169. PD MED Collaborative Group (2014) (opens in a new tab)
  170. Pharmaceutical Technology (2024) (opens in a new tab)
  171. Poewe et al. (2017) (opens in a new tab)
  172. Postuma et al. (2015) (opens in a new tab)
  173. Postuma et al. (2018) (opens in a new tab)
  174. Postuma et al. (2019) (opens in a new tab)
  175. Pringsheim et al. (2021) (opens in a new tab)
  176. Quintas et al. (2024) (opens in a new tab)
  177. Rabinak and Nirenberg (2010) (opens in a new tab)
  178. Rajagopalan et al. (2023) (opens in a new tab)
  179. Ramanzini et al. (2024) (opens in a new tab)
  180. Rascol and Fabbri (2026) (opens in a new tab)
  181. Rashid et al. (2026) (opens in a new tab)
  182. Reijnders et al. (2008) (opens in a new tab)
  183. Requip prescribing information (2021) (opens in a new tab)
  184. Reuters (2026) (opens in a new tab)
  185. Riesenberg et al. (2020) (opens in a new tab)
  186. Rizos et al. (2014) (opens in a new tab)
  187. Rizzo et al. (2016) (opens in a new tab)
  188. Rong et al. (2021) (opens in a new tab)
  189. Rosqvist et al. (2026) (opens in a new tab)
  190. Safarpour et al. (2015) (opens in a new tab)
  191. Sahlholm et al. (2025) (opens in a new tab)
  192. Sako et al. (2023) (opens in a new tab)
  193. Schini et al. (2020) (opens in a new tab)
  194. Schrag et al. (2000) (opens in a new tab)
  195. Schuepbach et al. (2013) (opens in a new tab)
  196. Selegiline hydrochloride capsules prescribing information (2014) (opens in a new tab)
  197. Siderowf et al. (2023) (opens in a new tab)
  198. Simon et al. (2020) (opens in a new tab)
  199. Simuni et al. (2024) (opens in a new tab)
  200. Sisodia et al. (2024) (opens in a new tab)
  201. Sohur et al. (2018) (opens in a new tab)
  202. Stocchi et al. (2010) (opens in a new tab)
  203. Su et al. (2025) (opens in a new tab)
  204. Thach et al. (2021a) (opens in a new tab)
  205. Thach et al. (2021b) (opens in a new tab)
  206. Thach et al. (2021c) (opens in a new tab)
  207. The Lewin Group (2026) (opens in a new tab)
  208. Torres-Russotto et al. (2026) (opens in a new tab)
  209. Verschuur et al. (2019) (opens in a new tab)
  210. Wang et al. (2026) (opens in a new tab)
  211. Weaver et al. (2009) (opens in a new tab)
  212. Weintraub et al. (2010) (opens in a new tab)
  213. Willis et al. (2012) (opens in a new tab)
  214. Willis et al. (2022) (opens in a new tab)
  215. World Parkinson Congress (2026) (opens in a new tab)
  216. Xadago prescribing information (2021) (opens in a new tab)
  217. Yang et al. (2020) (opens in a new tab)
  218. Yao et al. (2023) (opens in a new tab)
  219. Young et al. (2020) (opens in a new tab)
  220. Zhang et al. (2017) (opens in a new tab)
  221. Zhao et al. (2024) (opens in a new tab)